|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12...567891011121314151617 |
- ciprofloxacin oral / Generic mfg.
Trial completion: Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease (clinicaltrials.gov) - Feb 5, 2012
P2, N=33, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed
- topiramate / Generic mfg.
Enrollment change: New Medications to Treat Alcohol Dependence (clinicaltrials.gov) - Feb 2, 2012
P2, N=29, Completed, Sponsor: Bankole Johnson
Active, not recruiting --> Completed N=134 --> 29
- Trial initiation date: Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence (clinicaltrials.gov) - Feb 1, 2012
P2, N=382, Suspended, Sponsor: Technische Universit
N=134 --> 29 Initiation date: May 2011 --> May 2015
- Legalon (silibinin) / Viatris
New P2 trial: Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients (clinicaltrials.gov) - Jan 24, 2012
P2, N=44, Terminated, Sponsor: Rottapharm
- |||||||||| New P3 trial: A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients (clinicaltrials.gov) - Jan 18, 2012
P3, N=80, Active, not recruiting, Sponsor: SK Chemicals Co.,Ltd.
- Vectibix (panitumumab) / Amgen
Trial withdrawal: Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence (clinicaltrials.gov) - Jan 12, 2012
P3, N=0, Withdrawn, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: May 2011 --> May 2015 Not yet recruiting --> Withdrawn
- Vectibix (panitumumab) / Amgen
Enrollment change: Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence (clinicaltrials.gov) - Jan 12, 2012
P3, N=0, Withdrawn, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Withdrawn N=800 --> 0
- | asenapine / Generic mfg.
Enrollment open: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (clinicaltrials.gov) - Jan 3, 2012
P3b, N=550, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=800 --> 0 Not yet recruiting --> Recruiting
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment open, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Jan 2, 2012
P2, N=124, Recruiting, Sponsor: MolMed S.p.A.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment change: Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients (clinicaltrials.gov) - Dec 30, 2011
P2, N=1, Completed, Sponsor: Onconova Therapeutics, Inc.
Not yet recruiting --> Recruiting N=37 --> 1
- | imatinib / Generic mfg.
Trial completion, Stroma: Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Dec 28, 2011
P3, N=400, Completed, Sponsor: Scandinavian Sarcoma Group
N=37 --> 1 Active, not recruiting --> Completed
- aspirin / Generic mfg.
Enrollment change, Head-to-Head: Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin (clinicaltrials.gov) - Dec 19, 2011
P4, N=34, Terminated, Sponsor: University Hospital, Brest
Active, not recruiting --> Completed N=440 --> 34
- Enrollment change: Reoperation Rate Versus Clinical Recurrence After Ventral Hernia Repair (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=945, Completed, Sponsor: University Hospital Koge
N=440 --> 34 N=1200 --> 945
- Clinical: PAHEREP: Risk Factors for Morbidity After Parastomal Hernia Repair (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=199, Completed, Sponsor: University Hospital Koge
- Trial completion: Risk Factors for Morbidity After Incisional Hernia Repairs (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=3460, Completed, Sponsor: University Hospital Koge
N=1200 --> 945 Active, not recruiting --> Completed
- esomeprazole / Generic mfg.
Trial termination: APE-Study: Ablation of Barrett's Mucosa vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs. Placebo for Symptomatic Reflux Control After Successful Barrett's Ablation (clinicaltrials.gov) - Nov 27, 2011
P=N/A, N=68, Terminated, Sponsor: HSK Wiesbaden
Recruiting --> Terminated; Intermediate results have shown a significant difference in the outcome of ablation and non-ablation patients. Therefore, the study was stopped.
- || NeuVax (nelipepimut-S) / Dr. Reddy's
New P3 trial: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Nov 22, 2011
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
- Trial completion, Cytology: Urine Cytology and Utility in Bladder Recurrence (clinicaltrials.gov) - Nov 21, 2011
P=N/A, N=10, Completed, Sponsor: William Beaumont Hospitals
Therefore, the study was stopped. Active, not recruiting --> Completed
- | gemcitabine / Generic mfg.
Clinical: Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Nov 14, 2011
P2/3, N=116, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: RIT in MTC: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma (clinicaltrials.gov) - Nov 9, 2011
P2, N=0, Completed, Sponsor: Nantes University Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia (clinicaltrials.gov) - Nov 8, 2011
P1, N=10, Recruiting, Sponsor: University of New Mexico
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
New P1 trial: Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence (clinicaltrials.gov) - Nov 4, 2011
P1, N=24, Recruiting, Sponsor: Brain & Spine Surgeons of New York
- Enrollment change: PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) - Nov 2, 2011
P2, N=500, Recruiting, Sponsor: Arizona Molecular Imaging Center
Not yet recruiting --> Recruiting N=200 --> 500
- | gemcitabine / Generic mfg.
New P2/3 trial: Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Oct 23, 2011
P2/3, N=116, Recruiting, Sponsor: Seoul National University Hospital
- || New P3 trial: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Oct 18, 2011
P3, N=180, Recruiting, Sponsor: Mukoviszidose Institut gGmbH
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing (clinicaltrials.gov) - Oct 16, 2011
P4, N=44, Completed, Sponsor: University Health Network, Toronto
- Clinical: Cognitive-Behavioral Therapy (CBT) in Women Discontinuing Antidepressant for Pregnancy (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=15, Active, not recruiting, Sponsor: Massachusetts General Hospital
- |||| Azixa (verubulin) / Immune Pharma
Trial completion: Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Oct 12, 2011
P2, N=56, Completed, Sponsor: Myrexis Inc.
N=200 --> 500 Active, not recruiting --> Completed
- Trial completion: VAPRED: Echo Doppler (ED )Score and D-dimer (DD) Level in the Evaluation of VTE Recurrence After Anticoagulant Treatment Cessation (clinicaltrials.gov) - Oct 10, 2011
P4, N=222, Completed, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || trimethoprim/sulfamethoxazole / Generic mfg.
New P3 trial: ISROT: Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis (clinicaltrials.gov) - Oct 6, 2011
P3, N=140, Recruiting, Sponsor: University of Campinas, Brazil
- | New P2 trial, Surgery: Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer (clinicaltrials.gov) - Sep 25, 2011
P2, N=100, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
- warfarin / Generic mfg.
Trial termination: D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism (clinicaltrials.gov) - Sep 22, 2011
P=N/A, N=73, Terminated, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Terminated; Enrolment was halted prematurely because of the observed excess in recurrences
- warfarin / Generic mfg.
Enrollment change: D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism (clinicaltrials.gov) - Sep 22, 2011
P=N/A, N=73, Terminated, Sponsor: Universit
Recruiting --> Terminated; Enrolment was halted prematurely because of the observed excess in recurrences N=100 --> 73
- Enrollment open: A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=100, Recruiting, Sponsor: De La Salle University Medical Center
N=100 --> 73 Not yet recruiting --> Recruiting
- ||||| VivaGel (astodrimer vaginal) / Starpharma
New P2 trial: Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Sep 19, 2011
P2, N=205, Completed, Sponsor: Starpharma Pty Ltd
- | New P4 trial: Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF (clinicaltrials.gov) - Sep 14, 2011
P4, N=160, Completed, Sponsor: The Second Affiliated Hospital of Chongqing Medical University
- | mycophenolate mofetil / Generic mfg.
Enrollment change: Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid (clinicaltrials.gov) - Sep 12, 2011
P3, N=79, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Not yet recruiting --> Recruiting N=120 --> 79
- | Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy (clinicaltrials.gov) - Sep 12, 2011
P2, N=25, Completed, Sponsor: Austrian Breast & Colorectal Cancer Study Group
- | mycophenolate mofetil / Generic mfg.
Trial completion: Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid (clinicaltrials.gov) - Sep 12, 2011
P3, N=79, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
N=120 --> 79 Active, not recruiting --> Completed
- | pravastatin / Generic mfg.
Enrollment change: Japan Statin Treatment Against Recurrent Stroke (J-STARS) (clinicaltrials.gov) - Sep 11, 2011
P3, N=1578, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Completed N=3000 --> 1578
- everolimus / Generic mfg.
Trial termination: REVERT: Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection (clinicaltrials.gov) - Sep 7, 2011
P2, N=43, Terminated, Sponsor: Novartis Pharmaceuticals
N=3000 --> 1578 Recruiting --> Terminated
- Trial termination: The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases (clinicaltrials.gov) - Sep 1, 2011
P1/2, N=80, Terminated, Sponsor: Radboud University
Recruiting --> Terminated Recruiting --> Terminated; no accrual achieved
- | azathioprine / Generic mfg.
Trial completion: IMURELPOST: Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease (clinicaltrials.gov) - Aug 29, 2011
P3, N=83, Completed, Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Recruiting --> Terminated; no accrual achieved Active, not recruiting --> Completed
- || New P3 trial: Laparoscopic Versus Open Incisional Hernia Repair (clinicaltrials.gov) - Aug 17, 2011
P3, N=206, Completed, Sponsor: Erasmus Medical Center
- Trial termination: Prediction of Hepatitis C Recurrence in Liver Transplant Recipients (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=24, Terminated, Sponsor: Northwestern University
Active, not recruiting --> Completed Recruiting --> Terminated; This project is no longer being adequately supported to allow completion
- Enrollment change: Prediction of Hepatitis C Recurrence in Liver Transplant Recipients (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=24, Terminated, Sponsor: Northwestern University
Recruiting --> Terminated; This project is no longer being adequately supported to allow completion N=100 --> 24
- New P3 trial: Net-Pac;NetPac: Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (clinicaltrials.gov) - Aug 15, 2011
P3, N=5, Terminated, Sponsor: CHIR-Net
- Trial completion: Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=27, Completed, Sponsor: University of Medicine and Dentistry New Jersey
N=100 --> 24 Terminated --> Completed
- Trial completion: T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant (clinicaltrials.gov) - Aug 10, 2011
P2b, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Completed